Ann: Immutep Investor Update, page-96

A question that has been perplexing me since the bioreactor upgrade......

I'm wondering, when a drug is under patent does that mean the patent controller (in this case Immutep)
is responsible for production until patent expires.?.....
We have heard before Immuteps aim is for big pharma to be it's clients, essentially we research and
out licence, sell, collaborate, whatever, to whoever if research proven and becomes commercially viable?

On another note, ML, certainly some bigger players are taking an interest, solid day today, out of nowhere
though, see what happens over the next coupla days I suppose...